Product Images Lanreotide Acetate
View Photos of Packaging, Labels & Appearance
- Figure 1 - Figure 1
- Figure 10 - Figure 10
- Figure 11 - Figure 11
- Figure 12 - Figure 12
- Figure 13 - Figure 13
- Figure 14 - Figure 14
- Figure 15 - Figure 15
- Figure 16 - Figure 16
- Figure 17 - Figure 17
- Figure 18 - Figure 18
- Figure 19 - Figure 19
- Figure 2 - Figure 2
- Figure 20 - Figure 20
- Figure 21 - Figure 21
- Figure 22 - Figure 22
- Figure 23 - Figure 23
- Figure 24 - Figure 24
- Figure 25 - Figure 25
- Figure 26 - Figure 26
- Figure 3 - Figure 3
- Figure 4 - Figure 4
- Figure 5 - Figure 5
- Figure 6 - Figure 6
- Figure 7 - Figure 7
- Figure 8 - Figure 8
- Figure 9 - Figure 9
- carton label_120mg - carton label 120mg
- carton label_60mg - carton label 60mg
- carton label_90mg - carton label 90mg
- pouch label_120mg - pouch label 120mg
- pouch label_60mg - pouch label 60mg
- pouch label_90mg - pouch label 90mg
- pouch sticker label_120mg - pouch sticker label 120mg
- pouch sticker label_60mg - pouch sticker label 60mg
- pouch sticker label_90mg - pouch sticker label 90mg
- structure - structure
- syringe label_120mg - syringe label 120mg
- syringe label_60mg - syringe label 60mg
- syringe label_90mg - syringe label 90mg
Product Label Images
The following 39 images provide visual information about the product associated with Lanreotide Acetate NDC 69097-907 by Cipla Usa Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - Figure 1
Progression-free survival probability over time is depicted in the given data. The graph shows the survival outcomes of patients receiving Lanreotide Injection compared to those on placebo over several months. The hazard ratio and statistical significance level are also provided for comparison between the two groups.*
Figure 10 - Figure 10
Figure 11 - Figure 11
Figure 12 - Figure 12
Figure 13 - Figure 13
Figure 14 - Figure 14
Figure 15 - Figure 15
Figure 16 - Figure 16
Figure 17 - Figure 17
Figure 18 - Figure 18
Figure 19 - Figure 19
Figure 2 - Figure 2
Figure 20 - Figure 20
Figure 21 - Figure 21
Figure 22 - Figure 22
Figure 23 - Figure 23
Figure 24 - Figure 24
Figure 25 - Figure 25
Figure 26 - Figure 26
Figure 3 - Figure 3
Figure 4 - Figure 4
Figure 5 - Figure 5
Figure 6 - Figure 6
Figure 7 - Figure 7
Figure 8 - Figure 8
Figure 9 - Figure 9
carton label_120mg - carton label 120mg
carton label_60mg - carton label 60mg
carton label_90mg - carton label 90mg
pouch label_120mg - pouch label 120mg
pouch label_60mg - pouch label 60mg
pouch label_90mg - pouch label 90mg
pouch sticker label_120mg - pouch sticker label 120mg
This text provides information about Lanreotide injection, with a concentration of 120 mg/0.5 mL, intended for single-use only. The medication is manufactured by Pharmathen International in Rodopi, Greece, and is distributed by Cipla USA, Inc. The instructions advise leaving the injection at room temperature for 30 minutes before administration and discarding any unused portion. Additionally, the packaging includes a coding area labeled "Lok Non Varnished/Bxp."*
pouch sticker label_60mg - pouch sticker label 60mg
This text provides important information about Lanreotide injection in the dosage of 60 mg per 0.2 mL. The instructions state that it is for single use only, and any unused portion should be discarded. Before administration, the product should be left at room temperature for 30 minutes. The manufacturing information includes Pharmathen International, S.A. in Rodopi, Greece, and it is manufactured for Cipla USA, Inc. located in Warren, NJ. The text also includes a code labeled as 90325517 and mentions an area related to coding and expiration.*
pouch sticker label_90mg - pouch sticker label 90mg
This is a description of Lanreotide Injection with a concentration of 90 mg/0.3 mL. It is for single use only, and any unused portion should be discarded. The product needs to be left at room temperature for 30 minutes before administration. It is manufactured by Pharmathen International, S.A. in Rodopi, Greece, and manufactured for Cipla USA, Inc. located in Warren, NJ. The lot number is provided for tracking and expiry information.*
structure - structure
syringe label_120mg - syringe label 120mg
This is information about Lanreotide injection, with a concentration of 120 mg per 0.5 mL. It is for single use only, and any unused portion should be discarded. The manufacturing company is Pharmathen International, S.A. in Rodopi, Greece. The product is manufactured for Cila USA inc. located at Independence Boulevard, Suite 300, Warren, NJ 07059. The text also includes sections for Lot number, Expiration date, and Non Varnished/Coding Area.*
syringe label_60mg - syringe label 60mg
syringe label_90mg - syringe label 90mg
This text contains information about Lanreotide Injection for single use only. It is manufactured by Phamathen International, S.A. The injection comes in a vial with 0.03 mL of solution and should be discarded if any portion is left unused. The address mentioned is 300 Independence Boulevard, 07059 Warren, NJ.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
